يعرض 1 - 20 نتائج من 123 نتيجة بحث عن '"public health organization"', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
  7. 7
  8. 8
    Academic Journal
  9. 9
  10. 10
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المصدر: Cancer Urology; Том 12, № 2 (2016); 80-83 ; Онкоурология; Том 12, № 2 (2016); 80-83 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-2

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/579/551; https://oncourology.abvpress.ru/oncur/article/view/579/566; Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52(3):154–79.; Baca S.C., Prandi D., Lawrence M.S. et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153(3):666–77.; Grasso C.S., Wu Y.M., Robinson D.R. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):239–43.; de Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467(7315):543–9.; Beltran H., Yelensky R., Frampton G.M. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63(5): 920–6.; Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917–21.; Bryant H.E., Schultz N., Thomas H.D. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005;434(7035):913–7.; Fong P.C., Boss D.S., Yap T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123–34.; Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J Clin Oncol 2015;33(3):244–50.; Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382–92.; Ledermann J., Harter P., Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:856.; Mateo J., Carreira S., Sandhu S. et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373(18):167–708.; Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748–57.; Castro E., Goh C., Leongamornlert D. et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015;68(2):186–93.; Nelson H.D., Pappas M., Zakher B. et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2014;160(4):255–66.; Alanee S.R., Glogowski E.A., Schrader K.A. et al. Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed) 2014;6:15–30.; Akbari M.R., Wallis C.J., Toi A. et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer 2014;111(6):1238–40.; Bancroft E.K., Page E.C., Castro E. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 2014;66(3):489–99.; Mikropoulos C., Castro E., Bancroft E. et al. Identification of men with a genetic predisposition to prostate cancer: targeted screening in men at higher genetic risk and controls. Program and abstracts of the 2014 Genitourinary Cancers Symposium; January 30 – February 1, 2014; San Francisco, California. Abstr. 8.; Leongamornlert D., Mahmud N., Tymrakiewicz M. et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012;106(10):1697–701.; Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244–50.; Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65.; Robinson D., Van Allen E.M., Wu Y.M. et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28.; McCabe N., Turner N.C., Lord C.J. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66(16):8109–15.; Murai J., Huang S.Y., Das B.B. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72(2):5588–99.; Miller K.M., Tjeertes J.V., Coates J. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010;17(9):1144–51.; Chao O.S., Goodman O.B. Jr. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res 2014;12(12):1755–66.; Sternberg C.N., Petrylak D.P., Sartor O. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431–8.; Fong P.C., Yap T.A., Boss D.S. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28(15):2512–9.; Ceccaldi R., O’Connor K.W., Mouw K.W. et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015;75(4):628–34.; https://oncourology.abvpress.ru/oncur/article/view/579

  16. 16
  17. 17
    Academic Journal

    المؤلفون: article Editorial

    المصدر: Бюллетень сибирской медицины, Vol 4, Iss 3, Pp 118-122 (2005)

    وصف الملف: electronic resource

  18. 18
    Image
  19. 19
  20. 20